Beyond ovarian cancer, combination of PARPi and PD-(L)1 inhibitors has also been investigated in other tumour types, including bladder cancer as neoadjuvant treatment [283], platinum-sensitive CRPC [284], small cell lung cancer [285, 286], and breast cancer [276, 277, 287] (Table 1). This evidence concerns the gene CD274 and breast carcinoma.